Thiogenesis Therapeutics, Corp.
TTIPF
$0.58
$0.00-0.27%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.21% | 38.64% | 7.13% | 54.59% | 16.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 249.85% | 147.99% | 58.00% | -39.81% | -39.15% |
| Operating Income | -249.85% | -147.99% | -58.00% | 39.81% | 39.15% |
| Income Before Tax | -259.41% | -188.42% | -86.53% | 47.12% | 38.74% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -259.41% | -188.42% | -86.53% | 47.12% | 38.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -259.41% | -188.42% | -86.53% | 47.12% | 38.74% |
| EBIT | -249.85% | -147.99% | -58.00% | 39.81% | 39.15% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -226.42% | -181.90% | -81.36% | 53.81% | 47.52% |
| Normalized Basic EPS | -227.27% | -184.62% | -81.08% | 53.78% | 47.62% |
| EPS Diluted | -226.42% | -181.90% | -81.36% | 53.81% | 47.52% |
| Normalized Diluted EPS | -227.27% | -184.62% | -81.08% | 53.78% | 47.62% |
| Average Basic Shares Outstanding | 10.09% | 1.78% | 2.99% | 14.59% | 17.08% |
| Average Diluted Shares Outstanding | 10.09% | 1.78% | 2.99% | 14.59% | 17.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |